JAGUAR HEALTH INC (JAGX) Stock Overview
NASDAQ:JAGX - US47010C8881 - Common Stock
JAGX Key Statistics, Chart & Performance
The current stock price of JAGX is 1.65 USD. In the past month the price decreased by -17.68%. In the past year, price decreased by -94.28%.
JAGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.12 | 689.63B | ||
| JNJ | JOHNSON & JOHNSON | 17.78 | 428.12B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.25 | 248.21B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.91 | 246.50B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.22 | 243.56B | ||
| MRK | MERCK & CO. INC. | 11.07 | 212.84B | ||
| PFE | PFIZER INC | 7.29 | 140.58B | ||
| SNY | SANOFI-ADR | 11.05 | 119.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7 | 95.86B | ||
| GSK | GSK PLC-SPON ADR | 8.54 | 77.89B | ||
| ZTS | ZOETIS INC | 24.42 | 67.31B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 52.17 | 47.78B |
Related stock screener links
About JAGX
Company Profile
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Company Info
JAGUAR HEALTH INC
200 Pine Street Suite 400
San Francisco CALIFORNIA 94104 US
CEO: Lisa A. Conte
Employees: 49
Phone: 14153718300
JAGUAR HEALTH INC / JAGX FAQ
What is the stock price of JAGUAR HEALTH INC today?
The current stock price of JAGX is 1.65 USD. The price increased by 1.23% in the last trading session.
What is the ticker symbol for JAGUAR HEALTH INC stock?
The exchange symbol of JAGUAR HEALTH INC is JAGX and it is listed on the Nasdaq exchange.
On which exchange is JAGX stock listed?
JAGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JAGUAR HEALTH INC stock?
7 analysts have analysed JAGX and the average price target is 16.32 USD. This implies a price increase of 889.09% is expected in the next year compared to the current price of 1.65. Check the JAGUAR HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JAGUAR HEALTH INC worth?
JAGUAR HEALTH INC (JAGX) has a market capitalization of 3.58M USD. This makes JAGX a Nano Cap stock.
How many employees does JAGUAR HEALTH INC have?
JAGUAR HEALTH INC (JAGX) currently has 49 employees.
What are the support and resistance levels for JAGUAR HEALTH INC (JAGX) stock?
JAGUAR HEALTH INC (JAGX) has a resistance level at 2.12. Check the full technical report for a detailed analysis of JAGX support and resistance levels.
Is JAGUAR HEALTH INC (JAGX) expected to grow?
The Revenue of JAGUAR HEALTH INC (JAGX) is expected to grow by 24.03% in the next year. Check the estimates tab for more information on the JAGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy JAGUAR HEALTH INC (JAGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JAGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JAGX, evaluating the profitability, health, valuation and growth aspects
- JAGUAR HEALTH INC (JAGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JAGUAR HEALTH INC (JAGX) Sales and EPS estimates to see what analysts future expectations are.
- JAGUAR HEALTH INC (JAGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JAGUAR HEALTH INC (JAGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- JAGUAR HEALTH INC (JAGX) Stock Chart to make your own analysis
- JAGUAR HEALTH INC (JAGX) Latest news and press-releases to stay up to date.
Does JAGUAR HEALTH INC (JAGX) stock pay dividends?
JAGX does not pay a dividend.
When does JAGUAR HEALTH INC (JAGX) report earnings?
JAGUAR HEALTH INC (JAGX) will report earnings on 2025-11-11, before the market open.
What is the Price/Earnings (PE) ratio of JAGUAR HEALTH INC (JAGX)?
JAGUAR HEALTH INC (JAGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-53.55).
What is the Short Interest ratio of JAGUAR HEALTH INC (JAGX) stock?
The outstanding short interest for JAGUAR HEALTH INC (JAGX) is 1.53% of its float. Check the ownership tab for more information on the JAGX short interest.
JAGX Technical Analysis
JAGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JAGX. Both the profitability and financial health of JAGX have multiple concerns.
JAGX Financial Highlights
Over the last trailing twelve months JAGX reported a non-GAAP Earnings per Share(EPS) of -53.55. The EPS decreased by -21.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.21% | ||
| ROE | -931.08% | ||
| Debt/Equity | 4.32 |
JAGX Forecast & Estimates
7 analysts have analysed JAGX and the average price target is 16.32 USD. This implies a price increase of 889.09% is expected in the next year compared to the current price of 1.65.
For the next year, analysts expect an EPS growth of 89.56% and a revenue growth 24.03% for JAGX